Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.
about
Chikungunya Virus: In Vitro Response to Combination Therapy with Ribavirin and Interferon-α2aA pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infectionRibavirin Quantification in Combination Treatment of Chronic Hepatitis CAnalysis of Ribavirin Mutagenicity in Human Hepatitis C Virus InfectionRibavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infectionPharmacokinetics of ribavirin in patients with hepatitis C virus.Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.The single dose pharmacokinetics of ribavirin in subjects with chronic liver diseaseIncreased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple TherapyRole of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores.Clinical presentation and management of suspected ribavirin toxicosis in a dogPharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis CExpression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)
P2860
Q26247966-93721FBE-9EDC-4C40-BB40-977C14D0F4B5Q27023355-88622EA0-DB91-43F7-B45C-B3691A3693C4Q27473304-30B35FEA-BE12-43EE-89DA-58298A57239BQ27480933-3AA34C4C-1C5A-43F1-99CB-4072D958A4EDQ33815550-D2F7170C-D7A5-400E-B058-D1C578CFE6CFQ35169059-27810F2A-0F8C-4BF1-8415-C6BCE68F3496Q35648745-D519CFBA-B896-42BF-957B-E9E04EF9BC45Q35975174-3B0B7F3F-A415-4429-9E3A-99D59F2B269AQ36055167-099E4587-32EF-4573-B6C3-1711BA221753Q36180241-C5014670-BB87-4877-9968-48221069F578Q36236463-27853C64-1485-4A80-8F9A-4EDB51FCA38CQ36558322-1B63C5B0-0438-477E-A19D-52D37F7B0720Q36787397-C003613B-035C-40D2-9738-0E4F73692551Q36810865-E6ABF54E-1818-49E7-9EA1-0983AFA25DB4Q36877307-C4CA636B-852E-46EF-AA52-8873D3605707Q37397265-A16235F2-9E90-47F7-9868-593594DD7D0BQ56479686-F41C5E82-AD4F-4F5D-AD9C-565F6C545EBE
P2860
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Pharmacokinetics and absolute ...... by stable-isotope methodology.
@en
Pharmacokinetics and absolute ...... by stable-isotope methodology.
@nl
type
label
Pharmacokinetics and absolute ...... by stable-isotope methodology.
@en
Pharmacokinetics and absolute ...... by stable-isotope methodology.
@nl
prefLabel
Pharmacokinetics and absolute ...... by stable-isotope methodology.
@en
Pharmacokinetics and absolute ...... by stable-isotope methodology.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and absolute ...... by stable-isotope methodology
@en
P2093
P2860
P304
P356
10.1128/AAC.43.10.2451
P407
P577
1999-10-01T00:00:00Z